Skip to content

Public FDA record

Z-0042-2014: Brand: The ForeCYTE Breast Health Test, Mammary Aspiration Specimen Cytology Test (MASCT), MASCT System K

Recall record Z-0042-2014 for Atossa Genetics, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0042-2014
Company in FDA record
Atossa Genetics, Inc.
FDA classification date
Oct 28, 2013
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class I

Reason stated in the source

Atossa Genetics is recalling ForeCYTE Breast Health Test, Mammary Aspiration Specimen Cytology Test (MASCT) due to concerns raised by the U.S. Food and Drug Administration (FDA) in a warning letter received by Atossa in February 2013. The FDA raised concerns about (1) the current Instructions for Use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA cl

Source facts

Action
Atossa Genetics Inc. issued a press release to announce a voluntary recall on October 4, 2013. The firm started sending out the URGENT - VOLUNTARY PRODUCT RECALL NOTIFICATION ForeCYTE Breast Health Test; Mammary Aspiration Specimen Cytology Test (MASCT) RESPONSE REQUIRED letter to consignees on October 7, 2013. The letter identified the affected product, problem and actions to be taken. The firm initiated a voluntary recall to remove the ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test (MASCT) device from the market. The MASCT device has not been cleared by the FDA for the screening or diagnosis of breast cancer. In addition, the ForeCYTE Breast Health Test has not been cleared or approved by the FDA for any indication. The ForeCYTE Breast Health Test and the MASCT device are not a replacement for screening mammograms, diagnostic imaging tests, or biopsies. Patients should follow the recommendations and instructions of their physician with respect to breast cancer screening and diagnosis. Distributors are instructed to notify downstream customers and physicians are instructed to notify patients who have been tested using the MASCT and/or ForeCYTE systems. Consignees should return the Response Form back to Atossa. Distributors and customers should call 800-219-4629 to obtain a Returned Materials Authorization (RMA) number to return affected products. Customers with questions about this voluntary recall or Atossa's products, or would like assistance with the recall documentation may contact Atossa at 1-888-219-4629. Any problems experienced with the use of this product may be reported to the FDA at http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm, Online (form available to fax or mail), or call FDA 1-800-FDA-1088.
Initiated
2013-09-19
Root cause
No Marketing Application
Terminated
2014-08-19
Distribution
USA Nationwide Distribution in the states of: AL, CA, FL, GA, IL, IN, KY, MD, ME, MI, MO, NC, ND, NJ, NV, NY, OK, PA, SC, TN, TX, UT, VA, WA, Washington DC, and Puerto Rico.
Recall number
Z-0042-2014
Recall status
Terminated
CDRH record ID
122387
FDA classified
2013-10-28
Recall event number
66433

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗